AMENDMENTS TO THE CLAIMS

1. (Previously presented) An antibody comprising a specific binding member capable of binding an intracellular antigen, wherein said specific binding member comprises a polypeptide binding domain comprising an amino acid sequence as set out as residues 99 to 106 of SEQ ID NO: 2.

2. (Previously presented) An antibody comprising a specific binding member according to claim 1, which further comprises the polypeptide domains as set out as residues 31-36 and 51-66 of SEQ ID NO: 2.

3. (Previously presented) An antibody comprising a specific binding member according to claim 2, wherein said binding domains are carried by a human antibody framework.

4. (Previously presented) An antibody comprising a specific binding member according to claim 3, which comprises the polypeptide sequence of SEQ ID NO: 2.

5. (Previously presented) An antibody comprising a specific binding member which comprises a first specific binding member comprising an amino acid sequence as set out as residues 99 to 106 of SEQ ID NO: 2 in association with a second specific binding member comprising an amino acid sequence as set out as residues 88 to 98 of SEQ ID NO: 4.

6. (Previously presented) An antibody comprising a specific binding member which comprises a first specific binding member comprising an amino acid sequence as set out as residues 99 to 106 of SEQ ID NO: 2 in association with a second specific binding member comprising the polypeptide binding domains as set out as residues 23-33 and 49-55 of SEQ ID NO: 4.

7. (Previously presented) An antibody comprising a specific binding member which comprises a first specific binding member comprising an amino acid sequence as set out as residues 99 to 106 of SEQ ID NO: 2 in association with a second specific binding member comprising the polypeptide sequence of SEQ ID NO: 4.

8. (Previously presented) An antibody comprising a specific binding member which comprises a first specific binding member comprising an amino acid sequence as set out as residues 99 to 106 of SEQ ID NO: 2 in association with a second specific binding member comprising the polypeptide binding domains as set out as residues 23-33 and 49-55 of SEQ ID NO: 4, wherein said binding domains are carried by a human antibody framework.

9. (Previously presented) An antibody comprising a specific binding member according to Claim 8 in the form of an antibody F(ab')2 or scFv fragment.

10. (Cancelled) An antibody comprising a specific binding member according to Claim 1, wherein said antibody carries a label selected from the group consisting of a detectable label and a functional label.

11. (Previously presented) An isolated nucleic acid which comprises a sequence encoding a specific binding member as defined in Claim 1.

12. (Previously presented) A method of preparing an antibody comprising a specific binding member that comprises a polypeptide binding domain comprising an amino acid sequence as set out as residues 99 to 106 of SEQ ID NO: 2, said method comprising the steps of

expressing a nucleic acid which comprises a sequence encoding a specific binding member as defined in Claim 1 under conditions to bring about expression of said binding member, and

recovering the binding member.

13. (Previously presented) An antibody comprising a specific binding member according to Claim 1 for use in a method of treatment or diagnosis of the human or animal body.

14. (Previously presented) A method of preparing an antibody comprising a specific binding member capable of binding an intracellular antigen, which method comprises:

a) providing a starting repertoire of nucleic acids encoding a VH domain which lacks a CDR3 encoding region;

b) combining said repertoire with a donor nucleic acid encoding an amino acid sequence as set out as residues 99 to 106 of SEQ ID NO: 1 such that said donor nucleic acid is inserted into the missing CDR3 region, so as to provide a product repertoire of nucleic acids encoding a VH domain;

c) expressing the nucleic acids of said product repertoire;

d) selecting a specific binding member which has a maximum tumour:blood localization ratio in a test animal of greater than 3:1; and

e) recovering said binding member or the nucleic acid encoding said binding member.

15. (Previously presented) A method of preparing an antibody comprising a specific binding member capable of binding an intracellular antigen, which method comprises:

a) providing a starting repertoire of nucleic acids encoding a VH domain which lacks a CDR3 encoding region;

b) combining said repertoire which a donor nucleic acid encoding an amino acid sequence as set out as residues 99 to 106 of SEQ ID NO: 1 such that said donor nucleic acid is inserted into the missing CDR3 region, so as to provide a product repertoire of nucleic acids encoding a VH domain;

c) expressing the nucleic acids of said product repertoire;

d) selecting a specific binding member which has a maximum tumour:blood localization ratio in a test animal of greater than 3:1, and at said ratio, has a minimum organ to blood ratio of less than 1:1; and

e) recovering said binding member or the nucleic acid encoding said binding member.

16. (Previously presented) A method of treatment of a tumour in a human patient which comprises administering to said patient an effective amount of an antibody comprising a specific binding member as defined in Claim 1.

17. (Previously presented) An antibody comprising a specific binding member which comprises a first specific binding member comprising an amino acid sequence as set out as residues 31-36, 51-66 and 99 to 106 of SEQ ID NO: 2 in association with a second specific binding member comprising an amino acid sequence as set out as residues 88 to 98 of SEQ ID NO: 4.